Adequate bone marrow and organ function, as defined by the protocol
Adequate organ and bone marrow function:
Participant has adequate bone marrow and organ function as defined by the following laboratory values:
Patients must have adequate organ and bone marrow function within 14 days prior to registration, as defined below:
Adequate bone marrow and organ function
Adequate organ function defined as: Bone Marrow:
Subject has adequate bone marrow and organ function as shown by:
Patients must have adequate organ and bone marrow function within 14 days prior to registration, as defined by: leukocytes >= 2,000/mcL
Subjects with adequate organ and bone marrow function as defined below:
Adequate organ and bone marrow function
Patients must have adequate organ and bone marrow function =< 14 days prior to registration, as defined below:
Patients must have adequate bone marrow and organ function.
Adequate organ and bone marrow function defined by routine testing
Adequate bone marrow and organ function defined by laboratory values
Adequate bone marrow and organ function
Adequate organ and bone marrow function
Adequate bone marrow and organ function as assessed by the laboratory tests performed within 7 days before of treatment initiation.
Patients must have adequate organ and bone marrow function =< 14 days prior to registration, as defined below (Note: blood transfusion or growth factors is not permitted within 14 days of registration):
Adequate bone marrow and organ function
Adequate organ and bone marrow function determined within 14 days prior to enrollment defined as:
Patient has adequate bone marrow and organ function
Patient has adequate bone marrow and organ function
Patients must have adequate organ and bone marrow function
Patients must have adequate organ and bone marrow function within 14 days prior to registration, as defined below:
Life expectancy ? 12 weeks. 7. ECOG PS of 0 or 1 8. Adequate organ and bone marrow function 9. Ability to undergo during screening a tumor biopsy that is adequate for biomarker analysis.
Adequate organ and bone marrow function within the 21 days prior to randomization defined by:
Adequate bone marrow and organ function
Adequate bone marrow, organ function, cardiac and laboratory parameters
Adequate bone marrow, organ function, cardiac and laboratory parameters
Have adequate organ and bone marrow function.
Acceptable bone marrow and organ function at screening;
Adequate bone marrow function and organ function
Patient has adequate bone marrow and organ function.
Adequate bone morrow and organ function
Adequate bone marrow and organ function
Patient has adequate bone marrow and organ function.
Adequate organ or bone marrow function
Adequate bone marrow and organ function
Patient has adequate bone marrow and organ function
Adequate organ and bone marrow function
Adequate organ and bone marrow function as assessed by laboratory tests
Adequate bone marrow and organ function
Adequate bone marrow and organ function
Adequate bone marrow and organ function as determined by the consenting/enrolling investigator
Organ Function Requirements Patients without bone marrow metastases must have an ANC > 500/?l and platelet count >50,000/?l.
Patients must have adequate organ and bone marrow function 10 days prior to registration, as defined below:
Adequate bone marrow and organ function as defined as:
Adequate organ function for patients receiving crizotinib therapy as defined by the following criteria: Bone marrow function
Adequate organ and bone marrow function
Adequate organ and bone marrow function
